Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF -3.19%33 3-Year EBITDA Growth Rate is 54.00% as of May. 2026, which is 3% above its 10-year median of 52.50. GuruFocus rates TELIF with a GF Score™ of 33/100 and a GF Value™ of $0.39 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Telescope Innovations ranks better than 88.11% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Telescope Innovations was 54.00% per year. The lowest was -38.70% per year. And the median was 52.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Telescope Innovations 3-Year EBITDA Growth Rate Related Terms
TELIF vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Telescope Innovations's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.00% mean?
Telescope Innovations (TELIF) has a 3-Year EBITDA Growth Rate of 54.00% as of May. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Telescope Innovations and its competitors. This is near median its historical median of 52.50. According to the industry distribution chart, Telescope Innovations ranks #134 out of 1127 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Telescope Innovations' 3-Year EBITDA Growth Rate too high?
Telescope Innovations' current 3-Year EBITDA Growth Rate of 54.00% is near median its 10-year median of 52.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Telescope Innovations' value of 54.00% is 267.3% above this industry median. Based on the distribution chart, Telescope Innovations ranks #134 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telescope Innovations has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #134 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Telescope Innovations in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Telescope Innovations' value of 54.00% is 267.3% above this benchmark. While the company's 10-year median is 52.50 vs. the industry median of 14.70, Telescope Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current 3-Year EBITDA Growth Rate of 54.00% is 267.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Telescope Innovations and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current 3-Year EBITDA Growth Rate is 54.00%, which is near median its own 10-year median of 52.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.39, compared to a current price of $0.38 — trading 2.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 54.00%, which is near median its 10-year median of 52.50 and 267.3% above the Biotechnology industry median of 14.70. Telescope Innovations' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current 3-Year EBITDA Growth Rate is 54.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.38 is trading 2.1% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Fairly Valued.
Key valuation signals for TELIF:
3-Year EBITDA Growth Rate: 54.00% (near median its 10-year median of 52.50)
GF Value™: $0.39 vs. price of $0.38 (2.1% below fair value)
Industry Position: 267.3% above the Biotechnology median (#134 of 1127)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
33GF Score
Get the complete analysis for TELIF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
